Nurtec ODT Shortage Update: What Patients Need to Know in 2026

If you've had trouble filling your Nurtec ODT (rimegepant) prescription recently, you may be wondering: is there actually a shortage? The short answer in 2026 is no — Nurtec ODT is not on the FDA's official drug shortage list. But that doesn't mean every patient is getting their medication without trouble.

Here's the full picture: what's actually happening with Nurtec availability, why access issues occur, and exactly what you can do if you're struggling to fill your prescription.

Current Nurtec ODT Availability Status (2026)

As of 2026, Nurtec ODT (rimegepant 75 mg) is:

Not on the FDA Drug Shortages database — no formal shortage has been declared

Being manufactured by Pfizer, which acquired Biohaven (original manufacturer) in 2022

Available at most major chain pharmacies and orderable at independent pharmacies

Growing in demand as awareness of its dual acute/preventive approval increases among prescribers and patients

The supply chain itself is stable. Access issues, when they occur, are primarily driven by insurance barriers and selective pharmacy stocking — not manufacturing problems.

Why Are Patients Having Trouble Getting Nurtec Filled?

Even without a formal shortage, real-world barriers to Nurtec access fall into three main categories:

1. Insurance Prior Authorization Delays

Many insurance plans require prior authorization (PA) for Nurtec ODT. This means your insurer must formally approve coverage before your pharmacy can fill the prescription. The PA process typically involves your doctor submitting clinical notes showing that you've tried and failed on a cheaper medication (usually a triptan) first — a practice called step therapy.

While 97% of commercially insured patients reportedly have coverage for Nurtec, the PA process itself can take anywhere from a few days to several weeks, leaving patients without their medication in the interim.

2. High Cash Cost Without Insurance

The retail price for a single 8-tablet pack of Nurtec ODT runs approximately $1,075 to $1,415. Without insurance or savings programs, this is cost-prohibitive for most patients. Patients on Medicare face particular challenges, as the Pfizer copay card program is not available to those with government insurance.

3. Inconsistent Pharmacy Stocking

Nurtec ODT has no generic equivalent and costs pharmacies a significant amount to keep on the shelf. Smaller and rural pharmacies often don't stock it routinely. They can order it through their wholesale distributors in 24–48 hours, but many patients don't know to ask for this.

What Should Patients Do Right Now?

Here are practical steps based on the access barrier you're facing:

If Your Insurance Denied the Claim

Contact your doctor's office to initiate a prior authorization appeal

Call Pfizer's Migraine Patient Access Coordinators at 866-222-4183 for insurance navigation support

Ask about the bridge benefit: eligible commercially insured patients can access one free fill (up to 16 tablets) while PA is being processed

If Your Pharmacy Doesn't Have It in Stock

Ask your pharmacist to order it — most can get it from their wholesaler in 24–48 hours

Use medfinder to find pharmacies near you that currently have Nurtec ODT in stock — we call pharmacies on your behalf

Try a mail-order pharmacy through your insurance plan for a 90-day supply

If the Cost Is Prohibitive

With commercial insurance: Apply for Pfizer's copay card at nurtec.com/savings — eligible patients can pay as little as $0 per month (max $7,000/year benefit)

Without insurance: Pfizer's Patient Assistance Program may provide Nurtec ODT at no cost if you meet income requirements (≤ approximately $60,240/year for a single-person household)

Try a GoodRx or SingleCare discount coupon — can reduce cash price to around $923–$967 for an 8-tablet pack at some pharmacies

Looking Ahead: Nurtec Availability in the Future

Nurtec ODT's availability is expected to remain stable as long as Pfizer continues manufacturing and distributing the product. The patent extends to approximately 2039, meaning no generics are coming soon. The bigger issue for patients will continue to be cost and insurance coverage rather than supply.

For a deeper dive into why Nurtec can be hard to access even without a formal shortage, see our full explanation: Why is Nurtec ODT so hard to find?